ESMO 2018

A Big BiTE: Tetravalent BiTE Highly Potent in HER2-Positive Breast Cancer Models

October 19, 2018

A tetravalent BiTE against HER2 and CD3 showed potent antitumor activity in models of HER2-positive cancer, supporting further clinical development.

ESMO 2018

Real-World Experience Differs from Trial Results for Niraparib in Recurrent Ovarian Cancer

Leah Lawrence

October 19, 2018

Patients in the real world setting were initiated at a lower dose and experienced fewer side effects than trial participants.

$The management of metastatic breast cancer resistant or refractory to hormonal treatments, while sti$

ESMO 2018

Trastuzumab Biosimilar Demonstrated Equivalent Efficacy Across Clinical Settings

Leah Lawrence

October 19, 2018

Two biosimilars to trastuzumab were found to have efficacy equivalent to the sponsor product in both early-stage and metastatic breast cancer settings.

Researchers argue that immune therapies that target hormone-receptor-positive breast cancer is not t

ESMO 2018

Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC

Leah Lawrence

October 17, 2018

Researchers investigated whether the rates of immune-related adverse events linked to treatment with nivolumab or pembrolizumab were similar across 2 different cancer types.

Next post in ESMO 2018

ESMO 2018

A Big BiTE: Tetravalent BiTE Highly Potent in HER2-Positive Breast Cancer Models

Real-World Experience Differs from Trial Results for Niraparib in Recurrent Ovarian Cancer

Trastuzumab Biosimilar Demonstrated Equivalent Efficacy Across Clinical Settings

Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC

Want to read more?

First-Line Alectinib Effective in Asian Patients With ALK-Positive Advanced NSCLC